The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCAR-T 2022 | Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
Following a fantastic day at the 4th International Workshop on CAR-T (iwCAR-T) 2022 in Tampa, FL, leading experts David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, John Gribben, MD, DSc, FRCPath, FMed Sci, Barts and The London School of Medicine, Queen Mary University of London, London, UK, and Noelle Frey, MD, MSCE, University of Pennsylvania, Philadelphia, PA, share their highlights from the leukemia and lymphoma sessions. To begin with, the experts discuss the past, present, and future of CAR-T therapy in acute lymphoblastic leukemia (ALL), outlining strategies to improve relapse-free survival (RFS) in these patients. They then comment on the key challenges to CAR-T therapy in acute myeloid leukemia (AML) and highlight recent progress in this field. Finally, Dr Maloney, Dr Frey, and Prof. Gribben provide an overview of recent advances in CAR-T therapy for chronic lymphocytic leukemia (CLL), discussing the potential of ibrutinib in modulating the immune microenvironment and improving T-cell fitness in both CLL and in lymphoma, and emphasize the importance of determining the optimal window of opportunity for CAR-T in CLL.
